
REGENXBIO (RGNX) Stock Forecast & Price Target
REGENXBIO (RGNX) Analyst Ratings
Bulls say
Regenxbio is attractive because its lead RGX-202 program has a clear regulatory path, with rolling BLA submission beginning in 3Q26, completion in 1Q27, and potential accelerated approval in 2H27 backed by safety data from more than 60 patients and pivotal efficacy data. The company also has multiple near-term catalysts across its pipeline, including RGX-121 resubmission in 3Q26 and wet AMD topline results in 4Q26, while RGX-202 has shown >93% microdystrophin expression and clear functional improvement with a favorable safety profile. Financially, 2Q26 revenue reached $108.0M, net income was $22.7M, and pro forma cash rose to about $313M after a $100M AbbVie milestone and July 2026 financing, supporting operations into 4Q27.
Bears say
Regenxbio is facing a material setback after the FDA placed a clinical hold on RGX-121 following asymptomatic spine MRI findings in five CAMPSIITE participants, forcing a delay in the planned BLA resubmission and removing a key near-term commercialization opportunity. The fact that these patients were treated three to six years ago and that the prevalence and clinical significance of the findings remain unknown increases regulatory uncertainty, while the need for longer-term follow-up and additional data analysis weakens confidence in the asset’s benefit-risk profile. Although management says other Duchenne and retinal programs use different capsids and routes of administration, the hold underscores pipeline execution risk and suggests the company’s value remains highly dependent on unproven clinical readouts.
This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.
REGENXBIO (RGNX) Analyst Forecast & Price Prediction
Start investing in REGENXBIO (RGNX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About REGENXBIO (RGNX) Forecast
REGENXBIO (RGNX) Analyst Forecast & Price Prediction
Start investing in REGENXBIO (RGNX)
Order type
Buy in
Order amount
Est. shares
0 shares